Vaxcyte (PCVX) Financials

$36.57 +4.54 (+14.17%)

Closing price 05/20/2025 04:00 PM Eastern

Extended Trading

$35.30 -1.28 (-3.49%)

As of 08:26 AM Eastern

Annual Income Statements for Vaxcyte

This table shows Vaxcyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Income / (Loss) Attributable to Common Shareholders	-464	-402	-223	-100	-89	-50	-29
Consolidated Net Income / (Loss)	-464	-402	-223	-100	-89	-50	-29
Net Income / (Loss) Continuing Operations	-464	-402	-223	-100	-89	-50	-29
Total Pre-Tax Income	-464	-402	-223	-100	-89	-50	-29
Total Operating Income	-570	-468	-232	-104	-90	-54	-36
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	570	468	232	104	90	54	36
Selling, General & Admin Expense	93	61	40	25	16	8.55	5.39
Research & Development Expense	477	332	169	78	74	46	30
Other Operating Expenses / (Income)	0.00	75	23	0.00	-	-	-
Total Other Income / (Expense), net	106	66	8.77	3.59	0.36	4.34	6.05
Interest Expense	0.00	0.00	0.00	0.01	0.01	0.04	0.08
Interest & Investment Income	110	63	8.36	0.35	0.24	0.63	0.90
Other Income / (Expense), net	-4.38	2.87	0.42	3.25	0.13	3.74	5.22
Basic Earnings per Share	($3.80)	($4.14)	($3.44)	($1.93)	($3.02)	($13.25)	($8.12)
Weighted Average Basic Shares Outstanding	122.00M	97.16M	64.88M	51.92M	29.55M	3.80M	3.63M
Diluted Earnings per Share	($3.80)	($4.14)	($3.44)	($1.93)	($3.02)	($13.25)	($8.12)
Weighted Average Diluted Shares Outstanding	122.00M	97.16M	64.88M	51.92M	29.55M	3.80M	3.63M
Weighted Average Basic & Diluted Shares Outstanding	128.76M	108.41M	80.03M	51.92M	29.55M	3.80M	3.63M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00	$0.00	$0.00	-	-

This table shows Vaxcyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-141	-137	-103	-129	-95	-181	-93	-68	-60	-78	-58
Consolidated Net Income / (Loss)	-141	-137	-103	-129	-95	-181	-93	-68	-60	-78	-58
Net Income / (Loss) Continuing Operations	-141	-137	-103	-129	-95	-181	-93	-68	-60	-78	-58
Total Pre-Tax Income	-141	-137	-103	-129	-95	-181	-93	-68	-60	-78	-58
Total Operating Income	-181	-162	-140	-153	-114	-197	-113	-87	-71	-87	-59
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	181	162	140	153	114	197	113	87	71	87	59
Selling, General & Admin Expense	33	29	23	21	20	18	16	14	13	12	11
Research & Development Expense	148	134	117	132	95	104	97	73	58	52	48
Total Other Income / (Expense), net	40	25	37	24	19	16	20	19	11	8.22	0.66
Interest & Investment Income	33	36	28	24	22	17	18	16	11	6.63	1.19
Other Income / (Expense), net	7.14	-11	8.74	0.44	-2.34	-1.04	1.87	2.36	-0.32	1.59	-0.53
Basic Earnings per Share	($1.04)	($1.02)	($0.83)	($1.10)	($0.85)	($1.83)	($0.91)	($0.70)	($0.70)	($1.03)	($0.93)
Weighted Average Basic Shares Outstanding	135.69M	122.00M	123.69M	117.26M	111.69M	97.16M	101.67M	98.06M	86.21M	64.88M	61.99M
Diluted Earnings per Share	($1.04)	($1.02)	($0.83)	($1.10)	($0.85)	($1.83)	($0.91)	($0.70)	($0.70)	($1.03)	($0.93)
Weighted Average Diluted Shares Outstanding	135.69M	122.00M	123.69M	117.26M	111.69M	97.16M	101.67M	98.06M	86.21M	64.88M	61.99M
Weighted Average Basic & Diluted Shares Outstanding	129.00M	128.76M	124.64M	111.61M	108.80M	108.41M	95.15M	93.85M	93.71M	80.03M	78.98M

This table details how cash moves in and out of Vaxcyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Change in Cash & Equivalents	-9.36	-437	766	-316	327	-7.11	30
Net Cash From Operating Activities	-453	-297	-171	-121	-47	-47	-30
Net Cash From Continuing Operating Activities	-453	-297	-171	-121	-47	-47	-30
Net Income / (Loss) Continuing Operations	-464	-402	-223	-100	-89	-50	-29
Consolidated Net Income / (Loss)	-464	-402	-223	-100	-89	-50	-29
Depreciation Expense	7.00	3.16	2.83	1.80	1.41	1.23	1.04
Amortization Expense	-30	-28	5.67	3.06	0.00	0.00	-
Non-Cash Adjustments To Reconcile Net Income	16	77	35	2.25	13	1.96	-4.76
Changes in Operating Assets and Liabilities, net	18	54	8.91	-28	28	-0.06	2.75
Net Cash From Investing Activities	-2,006	-773	75	-212	-1.11	-1.20	-1.77
Net Cash From Continuing Investing Activities	-2,006	-773	75	-212	-1.11	-1.20	-1.77
Purchase of Property, Plant & Equipment	-22	-16	-5.84	-6.56	-1.16	-1.20	-1.77
Purchase of Investments	-3,087	-1,330	-103	-336	0.00	0.00	-
Sale and/or Maturity of Investments	1,200	624	183	131	0.00	0.00	-
Other Investing Activities, net	-97	-52	0.00	0.00	-	-	-
Net Cash From Financing Activities	2,449	640	862	18	375	42	62
Net Cash From Continuing Financing Activities	2,449	640	862	18	375	42	62
Issuance of Common Equity	2,463	644	862	15	0.41	0.12	0.12
Other Financing Activities, net	-14	-3.88	-0.86	3.01	0.57	-1.05	-0.28
Effect of Exchange Rate Changes	0.43	-6.69	0.14	-0.44	0.09	-0.34	-

This table details how cash moves in and out of Vaxcyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-41	-662	532	-93	214	-148	14	151	-454	556	40
Net Cash From Operating Activities	-166	-111	-61	-121	-159	-129	-58	-63	-48	-65	-39
Net Cash From Continuing Operating Activities	-166	-111	-61	-121	-159	-129	-58	-63	-48	-65	-39
Net Income / (Loss) Continuing Operations	-141	-137	-103	-129	-95	-181	-93	-68	-60	-78	-58
Consolidated Net Income / (Loss)	-141	-137	-103	-129	-95	-181	-93	-68	-60	-78	-58
Depreciation Expense	2.96	2.86	1.79	1.35	1.00	0.89	0.81	0.75	0.71	0.96	0.68
Amortization Expense	-3.00	-9.76	-3.40	-7.81	-8.90	-0.31	-13	-10	-4.36	0.42	1.43
Non-Cash Adjustments To Reconcile Net Income	15	-33	26	57	-34	7.51	41	12	16	13	12
Changes in Operating Assets and Liabilities, net	-40	66	18	-43	-22	44	6.48	3.08	0.08	-1.30	5.17
Net Cash From Investing Activities	123	-557	-917	-80	-451	-14	22	-334	-448	-36	35
Net Cash From Continuing Investing Activities	123	-557	-917	-80	-451	-14	22	-334	-448	-36	35
Purchase of Property, Plant & Equipment	-5.42	-4.02	-4.95	-7.78	-5.68	-5.25	-7.34	2.14	-5.61	-1.14	-0.84
Purchase of Investments	-314	-815	-1,233	-351	-688	-204	-210	-433	-484	-71	-18
Sale and/or Maturity of Investments	465	288	354	309	249	247	239	97	41	36	53
Other Investing Activities, net	-21	-26	-33	-31	-6.39	-52	-	-	0.00	-	-
Net Cash From Financing Activities	0.76	4.91	1,515	110	818	2.74	49	547	42	657	44
Net Cash From Continuing Financing Activities	0.76	4.91	1,515	110	818	2.74	49	547	42	657	44
Issuance of Common Equity	0.00	25	1,513	108	816	6.61	49	546	42	659	43
Other Financing Activities, net	0.76	-21	2.40	2.18	1.72	-3.87	-0.45	0.67	-0.23	-2.36	0.90
Effect of Exchange Rate Changes	1.17	1.35	-5.58	-1.41	6.06	-7.68	1.05	-0.08	0.02	0.80	0.05

This table presents Vaxcyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Total Assets	3,511	1,408	1,006	324	393	66
Total Current Assets	1,788	1,096	943	256	389	62
Cash & Equivalents	388	397	835	69	386	59
Short-Term Investments	1,359	683	97	177	0.00	-
Prepaid Expenses	41	16	11	10	2.80	2.75
Plant, Property, & Equipment, net	198	80	10	7.95	3.27	3.39
Total Noncurrent Assets	1,525	232	53	60	0.55	0.58
Long-Term Investments	1,388	163	27	27	0.00	-
Other Noncurrent Operating Assets	138	70	27	33	0.55	0.58
Total Liabilities & Shareholders' Equity	3,511	1,408	1,006	324	393	66
Total Liabilities	205	167	53	40	47	12
Total Current Liabilities	140	145	41	29	47	11
Accounts Payable	48	15	9.80	6.76	30	3.38
Accrued Expenses	65	113	24	13	17	7.08
Current Employee Benefit Liabilities	21	11	1.18	3.46	0.28	0.41
Other Current Liabilities	5.89	7.11	5.91	5.28	0.00	0.16
Total Noncurrent Liabilities	65	22	12	12	0.12	0.71
Other Noncurrent Operating Liabilities	65	22	12	12	0.11	0.69
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	3,306	1,240	954	284	346	-106
Total Preferred & Common Equity	3,306	1,240	954	284	346	-106
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,306	1,240	954	284	346	-106
Common Stock	4,698	2,165	1,476	583	544	2.97
Retained Earnings	-1,388	-924	-522	-299	-199	-109
Accumulated Other Comprehensive Income / (Loss)	-3.87	0.18	-0.36	-0.24	0.00	-

This table presents Vaxcyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	3,378	3,560	2,087	2,091	1,496	1,503	1,008	412
Total Current Assets	1,717	2,214	1,481	1,517	1,295	1,310	841	370
Cash & Equivalents	347	1,050	519	612	545	531	380	278
Short-Term Investments	1,325	1,130	934	875	721	756	442	84
Prepaid Expenses	45	33	29	31	30	23	19	7.53
Plant, Property, & Equipment, net	217	163	126	85	11	16	15	9.95
Total Noncurrent Assets	1,444	1,183	480	489	189	176	152	32
Long-Term Investments	1,279	1,093	399	413	169	154	128	3.98
Other Noncurrent Operating Assets	165	90	81	76	21	22	24	28
Total Liabilities & Shareholders' Equity	3,378	3,560	2,087	2,091	1,496	1,503	1,008	412
Total Liabilities	178	142	101	107	93	69	63	53
Total Current Liabilities	97	124	83	87	86	60	53	39
Accounts Payable	21	18	10	22	16	16	12	5.49
Accrued Expenses	64	84	59	55	57	34	33	24
Current Employee Benefit Liabilities	5.99	12	6.46	3.09	6.93	4.42	1.88	3.45
Other Current Liabilities	6.13	9.64	7.29	7.20	6.03	5.99	5.95	6.43
Total Noncurrent Liabilities	81	18	18	20	7.78	9.23	11	13
Other Noncurrent Operating Liabilities	81	18	18	20	7.78	9.23	11	13
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	3,200	3,418	1,986	1,984	1,403	1,433	945	359
Total Preferred & Common Equity	3,200	3,418	1,986	1,984	1,403	1,433	945	359
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,200	3,418	1,986	1,984	1,403	1,433	945	359
Common Stock	4,729	4,669	3,132	3,001	2,149	2,087	1,527	804
Retained Earnings	-1,529	-1,251	-1,148	-1,019	-744	-651	-583	-444
Accumulated Other Comprehensive Income / (Loss)	-0.32	0.14	1.82	2.89	-2.29	-2.52	0.05	-0.66

This table displays calculated financial ratios and metrics derived from Vaxcyte's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-21.85%	-119.30%	-133.73%	-8.52%	-79.05%	-67.98%	0.00%
EBIT Growth	-23.38%	-100.64%	-130.88%	-12.25%	-77.46%	-66.30%	0.00%
NOPAT Growth	-21.69%	-101.52%	-124.03%	-15.73%	-65.42%	-52.40%	0.00%
Net Income Growth	-15.33%	-80.00%	-123.31%	-12.17%	-77.46%	-70.51%	0.00%
EPS Growth	8.21%	-20.35%	-78.24%	36.09%	77.21%	-63.18%	0.00%
Operating Cash Flow Growth	-52.51%	-73.97%	-40.53%	-160.34%	1.10%	-54.75%	0.00%
Free Cash Flow Firm Growth	-73.66%	-123.64%	-18.96%	-352.22%	16.67%	0.00%	0.00%
Invested Capital Growth	7,129.62%	43.55%	-139.45%	127.09%	-700.89%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	2.75%	-30.09%	-33.95%	-8.74%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	4.07%	-31.99%	-32.06%	-9.90%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	5.71%	-30.76%	-32.32%	-11.14%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	8.61%	-34.31%	-28.44%	-8.48%	0.00%	0.00%	0.00%
EPS Q/Q Growth	17.57%	-23.95%	-16.22%	-143.57%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	3.70%	-27.27%	-9.03%	-49.74%	7.24%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	4.47%	-45.85%	-14.81%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	18.33%	92.28%	37.43%	188.47%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.92%	100.00%
Interest Burden Percent	80.83%	86.48%	96.40%	99.66%	99.74%	98.83%	97.27%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-20.41%	-36.67%	-36.12%	-31.78%	-44.63%	-93.21%	0.00%
Cash Return on Invested Capital (CROIC)	-334.43%	0.00%	0.00%	-1,133.08%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-20.41%	-36.67%	-36.12%	-31.78%	-26.74%	183.82%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-14.03%	-32.43%	-23.44%	-35.24%	-25.80%	47.26%	0.00%
Net Operating Profit after Tax (NOPAT)	-399	-328	-163	-73	-63	-38	-25
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-2.98%	-6.78%	-9.90%	-8.34%	-11.91%	-41.94%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-12.06%	-26.41%	-17.05%	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-574	-465	-232	-100	-89	-50	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-597	-490	-223	-96	-88	-49	-29
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.09	4.82	3.97	4.42	3.91	0.00	0.00
Price to Tangible Book Value (P/TBV)	3.09	4.82	3.97	4.42	3.91	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	41.31	0.00	0.00	89.90	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.96	-1.00	-0.99	-1.05	-1.11	-1.09	0.00
Leverage Ratio	1.08	1.10	1.08	1.14	1.15	1.22	0.00
Compound Leverage Factor	0.87	0.95	1.04	1.13	1.14	1.20	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	297.22%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	-197.22%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	29.26	20.21	42.82	17.22	16.87	10.35	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	40.10%	297.22%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	12.75	7.54	23.26	8.93	8.30	5.58	0.00
Quick Ratio	12.46	7.43	22.98	8.57	8.24	5.34	0.00
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-572	-330	-147	-124	-27	-33	0.00
Operating Cash Flow to CapEx	-2,018.22%	-1,847.78%	-2,920.68%	-1,859.29%	-4,219.73%	-3,945.19%	-1,718.33%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-73,668.10	-17,693.86	-3,912.67	-821.70	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	-85,298.50	-17,341.86	-6,661.14	-1,178.63	-406.21
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-88,219.00	-18,274.57	-6,819.00	-1,208.50	-429.85
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	171	-2.43	-4.31	11	-40	-5.04	0.00
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	174	1.88	-15	51	-35	-5.04	0.00
Enterprise Value (EV)	7,068	4,733	2,829	983	968	381	0.00
Market Capitalization	10,203	5,976	3,787	1,256	1,354	280	280
Book Value per Share	$26.52	$13.04	$12.07	$5.38	$6.79	($28.03)	$0.00
Tangible Book Value per Share	$26.52	$13.04	$12.07	$5.38	$6.79	($28.03)	$0.00
Total Capital	3,306	1,240	954	284	346	54	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-3,135	-1,243	-958	-273	-386	-59	0.00
Capital Expenditures (CapEx)	22	16	5.84	6.53	1.11	1.20	1.77
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-99	-130	-29	-18	-44	-8.31	0.00
Debt-free Net Working Capital (DFNWC)	1,648	951	902	228	342	51	0.00
Net Working Capital (NWC)	1,648	951	902	228	342	51	0.00
Net Nonoperating Expense (NNE)	65	75	61	28	27	12	4.61
Net Nonoperating Obligations (NNO)	-3,135	-1,243	-958	-273	-386	-59	0.00
Total Depreciation and Amortization (D&A)	-23	-25	8.51	4.86	1.41	1.23	1.04
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.80)	($4.14)	($3.44)	($1.93)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	122.00M	97.16M	64.88M	56.31M	0.00	0.00	0.00
Adjusted Diluted Earnings per Share	($3.80)	($4.14)	($3.44)	($1.93)	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	122.00M	97.16M	64.88M	56.31M	0.00	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($1.93)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	128.76M	108.41M	80.03M	51.92M	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-399	-328	-163	-73	-63	-38	-25
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-115,919.50	-14,345.14	-12,779.14	-1,260.23	-404.17
NOPAT to Interest Expense	0.00	0.00	-81,289.60	-10,367.00	-8,958.10	-947.68	-331.64
EBIT Less CapEx to Interest Expense	0.00	0.00	-118,840.00	-15,277.86	-12,937.00	-1,290.10	-427.81
NOPAT Less CapEx to Interest Expense	0.00	0.00	-84,210.10	-11,299.71	-9,115.96	-977.55	-355.28
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Vaxcyte's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-39.42%	8.55%	-7.74%	-68.73%	-65.94%	-135.81%	-116.26%	-102.17%	-108.02%	-209.66%	-124.52%
EBIT Growth	-48.82%	12.31%	-18.01%	-79.91%	-63.35%	-132.65%	-88.06%	-73.29%	-84.21%	-196.11%	-121.63%
NOPAT Growth	-57.94%	17.55%	-23.80%	-75.54%	-60.79%	-127.18%	-92.95%	-81.99%	-81.52%	-190.06%	-117.35%
Net Income Growth	-48.09%	24.18%	-11.29%	-88.33%	-57.16%	-131.65%	-59.99%	-40.81%	-55.09%	-173.26%	-117.61%
EPS Growth	-22.35%	44.26%	8.79%	-57.14%	-21.43%	-77.67%	2.15%	12.50%	-2.94%	-87.27%	-82.35%
Operating Cash Flow Growth	-4.49%	13.52%	-5.49%	-93.48%	-233.66%	-97.50%	-49.29%	-60.36%	-72.15%	-27.65%	-35.66%
Free Cash Flow Firm Growth	-72.11%	-105.70%	-403.09%	-413.30%	-351.24%	-207.67%	-17.24%	22.59%	52.23%	37.16%	-17.69%
Invested Capital Growth	195.97%	7,129.62%	558.57%	1,909.98%	1,757.18%	43.55%	-357.52%	-244.27%	-170.53%	-139.45%	44.22%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	3.65%	-35.76%	16.48%	-27.49%	36.74%	-59.95%	-30.79%	-25.38%	10.38%	-46.69%	-22.27%
EBIT Q/Q Growth	-0.15%	-32.17%	14.00%	-30.59%	40.92%	-77.87%	-31.10%	-18.57%	15.85%	-43.78%	-20.80%
NOPAT Q/Q Growth	-11.48%	-15.90%	8.54%	-33.64%	41.80%	-74.01%	-29.70%	-22.41%	17.77%	-47.79%	-22.33%
Net Income Q/Q Growth	-2.65%	-32.93%	19.87%	-35.45%	47.45%	-95.11%	-35.59%	-13.03%	22.53%	-34.76%	-19.34%
EPS Q/Q Growth	-1.96%	-22.89%	24.55%	-29.41%	53.55%	-101.10%	-30.00%	0.00%	32.04%	-10.75%	-16.25%
Operating Cash Flow Q/Q Growth	-49.26%	-83.50%	49.99%	23.71%	-23.53%	-123.83%	8.28%	-31.56%	26.88%	-69.19%	1.48%
Free Cash Flow Firm Q/Q Growth	-1.58%	-4.74%	-10.21%	-46.78%	-21.41%	-156.16%	-12.44%	-29.04%	17.22%	2.39%	25.75%
Invested Capital Q/Q Growth	45.68%	18.33%	7.75%	59.34%	3,560.07%	92.28%	-325.30%	-45.89%	-17.86%	37.43%	-234.11%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.02%	100.00%	99.98%	100.00%	100.00%	100.00%	100.00%	100.00%	99.62%	100.00%
Interest Burden Percent	81.03%	79.05%	78.61%	84.39%	81.34%	91.45%	83.36%	80.60%	84.55%	92.19%	97.99%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-19.66%	-20.41%	-21.06%	-29.08%	-29.83%	-36.67%	-34.00%	-29.42%	-37.56%	-36.12%	-52.31%
Cash Return on Invested Capital (CROIC)	-365.93%	-334.43%	-414.24%	-406.59%	-531.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-19.66%	-20.41%	-21.06%	-29.08%	-29.83%	-36.67%	-34.00%	-29.42%	-37.56%	-36.12%	-52.31%
Return on Equity Simple (ROE_SIMPLE)	-15.93%	0.00%	-14.85%	-25.03%	-22.02%	0.00%	-21.35%	-18.47%	-25.93%	0.00%	-48.43%
Net Operating Profit after Tax (NOPAT)	-127	-114	-98	-107	-80	-138	-79	-61	-50	-61	-41
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-0.58%	-1.08%	-0.22%	-1.31%	-1.05%	-3.92%	-1.50%	-0.81%	-1.63%	-2.84%	-4.94%
Return On Investment Capital (ROIC_SIMPLE)	-3.95%	-3.43%	-	-	-	-11.10%	-	-	-	-6.35%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-174	-173	-131	-153	-117	-198	-111	-85	-72	-85	-59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-174	-180	-133	-159	-125	-197	-123	-94	-75	-84	-57
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.52	3.09	3.73	4.14	3.28	4.82	3.41	3.26	3.18	3.97	3.96
Price to Tangible Book Value (P/TBV)	1.52	3.09	3.73	4.14	3.28	4.82	3.41	3.26	3.18	3.97	3.96
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.67	41.31	65.57	47.42	54.62	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.94	-0.96	-0.98	-0.96	-0.97	-1.00	-1.02	-1.00	-1.00	-0.99	-1.03
Leverage Ratio	1.06	1.08	1.05	1.05	1.06	1.10	1.08	1.06	1.08	1.08	1.15
Compound Leverage Factor	0.86	0.86	0.82	0.89	0.86	1.01	0.90	0.86	0.91	0.99	1.13
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	16.15	29.64	53.94	48.53	36.29	20.84	30.78	40.64	28.29	43.30	15.17
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	17.70	12.75	17.88	17.88	17.42	7.54	15.14	21.76	15.94	23.26	9.41
Quick Ratio	17.24	12.46	17.61	17.53	17.07	7.43	14.79	21.37	15.58	22.98	9.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-292	-287	-274	-249	-169	-140	-54	-48	-38	-45	-46
Operating Cash Flow to CapEx	-3,065.52%	-2,770.48%	-1,227.17%	-1,560.13%	-2,802.47%	-2,451.66%	-784.14%	0.00%	-850.24%	-5,721.14%	-4,572.72%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	249	171	145	134	84	-2.43	-32	-7.41	-5.08	-4.31	-6.89
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	165	174	176	142	89	1.88	-25	-13	-12	-15	5.46
Enterprise Value (EV)	1,911	7,068	9,481	6,363	4,600	4,733	3,350	3,239	2,050	2,829	1,057
Market Capitalization	4,862	10,203	12,754	8,215	6,500	5,976	4,784	4,680	3,000	3,787	1,424
Book Value per Share	$24.85	$26.52	$30.62	$18.26	$17.76	$13.04	$14.95	$15.30	$11.80	$12.07	$6.06
Tangible Book Value per Share	$24.85	$26.52	$30.62	$18.26	$17.76	$13.04	$14.95	$15.30	$11.80	$12.07	$6.06
Total Capital	3,200	3,306	3,418	1,986	1,984	1,240	1,403	1,433	945	954	359
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-2,951	-3,135	-3,273	-1,852	-1,900	-1,243	-1,434	-1,441	-950	-958	-366
Capital Expenditures (CapEx)	5.42	4.02	4.95	7.78	5.68	5.25	7.34	-2.14	5.61	1.14	0.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-52	-99	-90	-54	-57	-130	-56	-37	-34	-29	-32
Debt-free Net Working Capital (DFNWC)	1,620	1,648	2,090	1,399	1,430	951	1,210	1,250	788	902	330
Net Working Capital (NWC)	1,620	1,648	2,090	1,399	1,430	951	1,210	1,250	788	902	330
Net Nonoperating Expense (NNE)	14	24	5.18	22	15	43	14	7.34	11	17	17
Net Nonoperating Obligations (NNO)	-2,951	-3,135	-3,273	-1,852	-1,900	-1,243	-1,434	-1,441	-950	-958	-366
Total Depreciation and Amortization (D&A)	-0.04	-6.89	-1.61	-6.46	-7.90	0.58	-12	-9.44	-3.65	1.38	2.12
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.04)	($1.02)	($0.83)	($1.10)	($0.85)	($1.83)	($0.91)	($0.70)	($0.70)	($1.03)	($0.93)
Adjusted Weighted Average Basic Shares Outstanding	135.69M	122.00M	123.69M	117.26M	111.69M	97.16M	101.67M	98.06M	86.21M	64.88M	61.99M
Adjusted Diluted Earnings per Share	($1.04)	($1.02)	($0.83)	($1.10)	($0.85)	($1.83)	($0.91)	($0.70)	($0.70)	($1.03)	($0.93)
Adjusted Weighted Average Diluted Shares Outstanding	135.69M	122.00M	123.69M	117.26M	111.69M	97.16M	101.67M	98.06M	86.21M	64.88M	61.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	129.00M	128.76M	124.64M	111.61M	108.80M	108.41M	95.15M	93.85M	93.71M	80.03M	78.98M
Normalized Net Operating Profit after Tax (NOPAT)	-127	-114	-98	-107	-80	-138	-79	-61	-50	-61	-41
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Vaxcyte's Financials

When does Vaxcyte's fiscal year end?

According to the most recent income statement we have on file, Vaxcyte's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Vaxcyte's net income changed over the last 6 years?

Vaxcyte's net income appears to be on an upward trend, with a most recent value of -$463.93 million in 2024, rising from -$29.49 million in 2018. The previous period was -$402.27 million in 2023. View Vaxcyte's forecast to see where analysts expect Vaxcyte to go next.

What is Vaxcyte's operating income?

Vaxcyte's total operating income in 2024 was -$569.55 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $569.55 million

How has Vaxcyte revenue changed over the last 6 years?

Over the last 6 years, Vaxcyte's total revenue changed from $0.00 in 2018 to $0.00 in 2024, a change of 0.0%.

How much debt does Vaxcyte have?

Vaxcyte's total liabilities were at $205.50 million at the end of 2024, a 22.7% increase from 2023, and a 1,647.3% increase since 2019.

How much cash does Vaxcyte have?

In the past 5 years, Vaxcyte's cash and equivalents has ranged from $58.98 million in 2019 to $834.66 million in 2022, and is currently $387.88 million as of their latest financial filing in 2024.

How has Vaxcyte's book value per share changed over the last 6 years?

Over the last 6 years, Vaxcyte's book value per share changed from 0.00 in 2018 to 26.52 in 2024, a change of 2,652.4%.

Related Companies

This page (NASDAQ:PCVX) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Financials

Frequently Asked Questions About Vaxcyte's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaxcyte (PCVX) Financials

Annual Income Statements for Vaxcyte

Quarterly Income Statements for Vaxcyte

Annual Cash Flow Statements for Vaxcyte

Quarterly Cash Flow Statements for Vaxcyte

Annual Balance Sheets for Vaxcyte

Quarterly Balance Sheets for Vaxcyte

Annual Metrics And Ratios for Vaxcyte

Quarterly Metrics And Ratios for Vaxcyte

Frequently Asked Questions About Vaxcyte's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools